News
Final Phase 1 Trial Results Demonstrate Galectin Therapeutics’ GR-MD-02 is Safe With Potential for Therapeutic Effect on Fibrosis in NASH Patients With Advanced Fibrosis
January 7, 2015 | Press ReleaseFinal Phase 1 Trial Results Demonstrate Galectin Therapeutics’ GR-MD-02 is Safe with Potential for Therapeutic Effect on Fibrosis in NASH Patients with Advanced Fibrosis
January 7, 2015 | Press ReleaseGalectin Therapeutics to Present at 7th Annual LD Micro Main Event Conference
December 1, 2014 | Press ReleaseGalectin Therapeutics Reports Third Quarter 2014 Financial Results and Provides Update on Company’s Development Program
November 10, 2014 | Press ReleaseHighlights
View Galectin Therapeutics’ Latest Corporate Presentation
January 7, 2015 | PresentationView a webcast from Galectin Therapeutics’ presentation at LD Micro
December 4, 2014 | WebcastView a presentation from AASLD’s The Liver Meeting detailing Phase 1 clinical trial results of GR-MD-02 in NASH
November 10, 2014 | PresentationView a webcast from Galectin Therapeutics’ presentation at Aegis Healthcare & Technology Conference
September 12, 2014 | WebcastView a presentation detailing second cohort results of Phase 1 clinical trial of GR-MD-02 in NASH
July 30, 2014 | Presentation
Galectin Therapeutics, Inc.
NASDAQ: GALT
3.28-0.17 Stock price updates every 30 minutes.